DDInter624 DDInter1472
Efavirenz (brand names Sustiva® and Stocrin®) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1. For HIV infection that has not previously been treated, efavirenz and lamivudine in combination with zidovudine or tenofovir is the preferred NNRTI-based regimen. Efavirenz is also used in combination with other antiretroviral agents as part of an expanded postexposure prophylaxis regimen to prevent HIV transmission for those exposed to materials associated with a high risk for HIV transmission.
Pioglitazone is an antihyperglycemic used as an adjunct to diet, exercise, and other antidiabetic medications to manage type 2 diabetes mellitus.[L11416,L11419,L11422,L11425] It is administered as a racemic mixture, though there is no pharmacologic difference between the enantiomers and they appear to interconvert _in vivo_ with little consequence. The thiazolidinedione class of medications, which also includes [rosiglitazone] and [troglitazone], exerts its pharmacological effect primarily by promoting insulin sensitivity and the improved uptake of blood glucose via agonism at the peroxisome proliferator-activated receptor-gamma (PPARγ). PPARs are ligand-activated transcription factors that are involved in the expression of more than 100 genes and affect numerous metabolic processes, most notably lipid and glucose homeostasis. Thiazolidinediones, including pioglitazone, have fallen out of favor in recent years due to the presence of multiple adverse effects and warnings regarding their use (e.g. congestive heart failure, bladder cancer) and the availability of safer and more effective alternatives for patients with type 2 diabetes mellitus.
Efavirenz {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Pioglitazone
Efavirenz {u} (Compound) causes {v} (Side Effect) Hepatic failure
Hepatic failure {u} (Side Effect) is caused by {v} (Compound) Pioglitazone
Efavirenz {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Rosiglitazone
Rosiglitazone {u} (Compound) resembles {v} (Compound) Pioglitazone
Efavirenz {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is associated with {v} (Disease) type 2 diabetes mellitus
type 2 diabetes mellitus {u} (Disease) is treated by {v} (Compound) Pioglitazone
Efavirenz {u} (Compound) causes {v} (Side Effect) Hepatic failure
Hepatic failure {u} (Side Effect) is caused by {v} (Compound) Rosiglitazone
Rosiglitazone {u} (Compound) resembles {v} (Compound) Pioglitazone
Efavirenz {u} (Compound) causes {v} (Side Effect) Hypersensitivity
Hypersensitivity {u} (Side Effect) is caused by {v} (Compound) Levonorgestrel
Levonorgestrel {u} may cause a minor interaction that can limit clinical effects when taken with {v} Pioglitazone
Efavirenz {u} (Compound) causes {v} (Side Effect) Haematuria
Haematuria {u} (Side Effect) is caused by {v} (Compound) Raltegravir
Raltegravir {u} may cause a minor interaction that can limit clinical effects when taken with {v} Pioglitazone
Efavirenz {u} (Compound) treats {v} (Disease) acquired immunodeficiency syndrome
acquired immunodeficiency syndrome {u} (Disease) downregulates {v} (Gene) MYC
MYC {u} (Gene) is upregulated by {v} (Compound) Pioglitazone
Efavirenz {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Nifedipine
Nifedipine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Pioglitazone
Efavirenz {u} (Compound) causes {v} (Side Effect) Multiple fractures
Multiple fractures {u} (Side Effect) is caused by {v} (Compound) Phenytoin
Phenytoin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pioglitazone
Efavirenz (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Pioglitazone (Compound)
Efavirenz (Compound) causes Hepatic failure (Side Effect) and Hepatic failure (Side Effect) is caused by Pioglitazone (Compound)
Efavirenz (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Rosiglitazone (Compound) and Rosiglitazone (Compound) resembles Pioglitazone (Compound)
Efavirenz (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is associated with type 2 diabetes mellitus (Disease) and type 2 diabetes mellitus (Disease) is treated by Pioglitazone (Compound)
Efavirenz (Compound) causes Hepatic failure (Side Effect) and Hepatic failure (Side Effect) is caused by Rosiglitazone (Compound) and Rosiglitazone (Compound) resembles Pioglitazone (Compound)
Efavirenz (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Levonorgestrel (Compound) and Levonorgestrel may cause a minor interaction that can limit clinical effects when taken with Pioglitazone
Efavirenz (Compound) causes Haematuria (Side Effect) and Haematuria (Side Effect) is caused by Raltegravir (Compound) and Raltegravir may cause a minor interaction that can limit clinical effects when taken with Pioglitazone
Efavirenz (Compound) treats acquired immunodeficiency syndrome (Disease) and acquired immunodeficiency syndrome (Disease) downregulates MYC (Gene) and MYC (Gene) is upregulated by Pioglitazone (Compound)
Efavirenz (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Nifedipine (Compound) and Nifedipine may cause a minor interaction that can limit clinical effects when taken with Pioglitazone
Efavirenz (Compound) causes Multiple fractures (Side Effect) and Multiple fractures (Side Effect) is caused by Phenytoin (Compound) and Phenytoin may cause a moderate interaction that could exacerbate diseases when taken with Pioglitazone